Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin-Reference-Cited by-同舟云学术

Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin

Published:1998-07 Issue:7 Volume:22 Page:625-629
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Fukushima Toshihiro,Inoue Hitoshi,Takemura Haruyuki,Kishi Shinzi,Yamauchi Takahiro,Inai Kunihiro,Nakayama Takashi,Imamura Shin,Urasaki Yoshimasa,Nakamura Toru,Ueda Takanori

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference28 articles.

1. Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their β anomers;Arcamone;Cancer Treat Rep,1976

2. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia;Berman;Blood,1991

3. Action mechanism of idarubicin (4-demethoxydaunorubicin) as compared with daunorubicin in leukemic cells;Fukushima;Int J Hematol,1993

4. Influence of idarubicinol on the antileukemic effect of idarubicin;Fukushima;Leukemia Res,1994

5. 4-Demethoxydaunorubicin (idarubicin) in combination with 1-β-d-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia;Berman;Cancer Res,1989

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Influence of lipophilicity of anthracyclines on the interactions with cholesterol in the model cell membranes – Langmuir monolayer and SEIRAS studies;Colloids and Surfaces B: Biointerfaces;2022-03

Mechanisms of drug resistance in acute myeloid leukemia

;OncoTargets and Therapy;2019-03

3. Low-dose triptolide in combination with idarubicin induces apoptosis in AML leukemic stem-like KG1a cell line by modulation of the intrinsic and extrinsic factors;Cell Death & Disease;2013-12

4. Idarubicin is superior to daunorubicin in remission induction of de novo acute myeloid leukemia patients with high MDR1 expression;Pharmacogenomics;2013-01

5. Fatty acid based hyperbranched polymeric nanoparticles for hydrophobic drug delivery;Drug Development and Industrial Pharmacy;2010-04-06